Abstract
COVID-19 seroprevalence changes over time, with infection, vaccination, and waning immunity. Seroprevalence estimates are needed to determine when increased COVID-19 vaccination coverage is needed, and when booster doses should be considered, to reduce the spread and disease severity of COVID-19 infection. We use an age-structured model including infection, vaccination and waning immunity to estimate the distribution of immunity to COVID-19 in the Canadian population. This is the first mathematical model to do so. We estimate that 60–80% of the Canadian population has some immunity to COVID-19 by late Summer 2021, depending on specific characteristics of the vaccine and the waning rate of immunity. Models results indicate that increased vaccination uptake in age groups 12–29, and booster doses in age group 50+ are needed to reduce the severity COVID-19 Fall 2021 resurgence.
Funder
Natural Sciences and Engineering Research Council of Canada
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference36 articles.
1. SARS-CoV-2 seroprevalence among blood donors in Québec, and analysis of symptoms associated with seropositivity: a nested case-control study
2. SARS‐CoV‐2 seroprevalence among blood donors after the first COVID‐19 wave in Canada
3. Serotrackerhttps://serotracker.com/en/Explore
4. Task Force Funded Research; Technical Reporthttps://www.covid19immunitytaskforce.ca/task-force-research/
5. Immunity Monitoring Report: Cumulative SARS-CoV-2 Seropositivity in Canadahttps://www.covid19immunitytaskforce.ca
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献